- Open Access
Autophagy impairment: a crossroad between neurodegeneration and tauopathies
© Nassif and Hetz; licensee BioMed Central Ltd. 2012
Received: 11 September 2012
Accepted: 14 September 2012
Published: 21 September 2012
Most neurodegenerative diseases involve the accumulation of misfolded proteins in the nervous system. Impairment of protein degradation pathways such as autophagy is emerging as a consistent and transversal pathological phenomenon in neurodegenerative diseases, including Alzheimer's, Huntington's, and Parkinson's disease. Genetic inactivation of autophagy in mice has demonstrated a key role of the pathway in maintaining protein homeostasis in the brain, triggering massive neuronal loss and the accumulation of abnormal protein inclusions. However, the mechanism underlying neurodegeneration due to autophagy impairment remains elusive. A paper in Molecular Neurodegeneration from Abeliovich's group now suggests a role for phosphorylation of Tau and the activation of glycogen synthase kinase 3β (GSK3β) in driving neurodegeneration in autophagy-deficient neurons. We discuss the implications of this study for understanding the factors driving neurofibrillary tangle formation in Alzheimer's disease and tauopathies.
See research article http://www.molecularneurodegeneration.com/content/7/1/48
The progressive accumulation of misfolded proteins in the brain is implicated in a vast group of human diseases, including the most prevalent neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease, and amyotrophic lateral sclerosis. These diseases are classified as protein misfolding disorders (PMDs) . Despite representing an extensive and active field of research, in most cases the factors driving protein misfolding and neurodegeneration in the most common sporadic PMD cases remain poorly understood. Alteration in protein homeostasis networks is emerging as a factor driving neuronal dysfunction, where disruption in protein quality control mechanisms and protein clearance pathways may contribute to the accumulation of abnormally folded proteins in the brain.
AD is characterized by a massive accumulation of lysosomal-related vesicles in the degenerating neurons. Several studies have identified specific defects in the autophagy process in AD mouse models. For example, Ralph Nixon's group proposed that presenilin-1 (PS1) directly regulates the acidification of lysosomes by controlling the targeting of v-ATPase to these vesicles . AD-linked PS1 mutations result in defective lysosomal proteolysis, having a detrimental impact on protein homeostasis and neuronal function . In fact, genetic strategies to restore lysosomal function prevented neuropathology and cognitive deficits of an AD mouse model . Remarkably, restoring lysosomal function in AD mice significantly decreased the accumulation of amyloid-β in the brain , placing autophagy impairment as a possible upstream component in the etiology of AD.
Accumulating evidence suggests that autophagy activity decreases during aging, which is the major risk factor for developing PMDs. In agreement with this idea, strategies that stimulate autophagy (such as rapamycin or resveratrol treatments, and caloric restriction) have potent anti-aging effects in vivo . The first evidence indicating an important function of basal autophagy in the brain came from studies describing the effects of the genetic ablation of essential autophagy regulators such as Atg5 and Atg7 in mice [5, 6]. Autophagy-deficient neurons undergo spontaneous degenerative changes that resemble those related to PMD, involving the accumulation of ubiquitin-positive inclusions, neuronal loss, motor dysfunction, and premature death [5, 6]. Although it was initially assumed that the accumulation of protein inclusions was the trigger of neurodegeneration in those models, an elegant study demonstrated that ablating the adapter protein p62/SQSTM1 abrogated the accumulation of protein aggregates in atg7 deficient neurons, but did not prevent neuronal dysfunction . Thus, the molecular mechanisms explaining the occurrence of neurodegeneration due to autophagy impairment remain an important open question.
In Molecular Neurodegeneration, Inoue and coworkers identified a surprising mechanism underlying degeneration in autophagy-deficient neurons, involving the engagement of a phospho-Tau-dependent pathway . Accumulation of phosphorylated Tau in neurofibrillary tangles represents one of the major hallmarks of AD and other tauopathies, including frontotemporal dementia . The authors generated two conditional Atg7 knockout mice focusing on the post-natal deletion in specific brain areas including hippocampal and glutamatergic neurons within the cerebral cortex, and dopaminergic neurons in the midbrain (Dat-Atg7 cKO). This strategy recapitulated previous findings obtained with developmental inactivation of atg7 in neurons, including autophagy impairment, neuronal loss, and accumulation of ubiquitin-positive inclusions. Due to increasing reports suggesting the occurrence of autophagy impairment in PMDs, the authors examined the levels of the most common proteins accumulated in these diseases. Unexpectedly, an evident redistribution of phospho-Tau into inclusions was detected in Atg7-deficient neurons, in addition to one of its kinases, glycogen synthase kinase 3β (GSK3β). In contrast, no accumulation of amyloid precursor protein (APP), TDP-43 or α-synuclein was observed (Figure 1b) . Interestingly, a recent report also suggested that stimulation of mammalian target of rapamycin (mTOR)-independent autophagy can protect neurons against degeneration in mutant Tau transgenic mice due to its degradation of Tau aggregates , reinforcing the idea that autophagy also controls Tau levels. A systematic characterization of Tau phosphorylation sites in Atg7-deficient neurons indicated that the pattern observed was similar to an early 'pre-tangle' state that does not lead to formation of amyloid or fibrillar structures. Using a pharmacological approach to inhibit Tau phosphorylation or the genetic ablation of tau in mice, the authors partially reverted the neurodegenerative effects of Atg7 deficiency. Remarkably, the formation of ubiquitin/p62-positive inclusions remained intact after these manipulations, suggesting that Tau-mediated neurodegeneration may represent (i) a downstream pathological event of abnormal protein aggregation, or (ii) a parallel phenomenon triggered by an unknown mechanism. It will be interesting to determine if deletion of p62 in Atg7 knockout mice affects Tau/GSK3β redistribution and phosphorylation.
This study suggests for the first time a connection between autophagy impairment, Tau pathology, and neurodegeneration (Figure 1c), and given the emerging association between autophagy dysfunction and aging, provides clues about the possible cause of the most common sporadic forms of neurodegenerative diseases, offering an interesting possibility for future therapeutic intervention.
We received support from Alzheimer's Association, FONDECYT 1100176, FONDAP 15010006, ACT1109, Instituto Milenio P09-015-F. In addition we received support from the Michael J Fox Foundation for Parkinson Research, the Muscular Dystrophy Association, and the ALS Therapy Alliance.
- Matus S, Glimcher LH, Hetz C: Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Curr Opin Cell Biol. 2011, 23: 239-252. 10.1016/j.ceb.2011.01.003.PubMedView ArticleGoogle Scholar
- Rubinsztein DC, Mariño G, Kroemer G: Autophagy and aging. Cell. 2011, 146: 682-695. 10.1016/j.cell.2011.07.030.PubMedView ArticleGoogle Scholar
- Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA: Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010, 141: 1146-1158. 10.1016/j.cell.2010.05.008.PubMedPubMed CentralView ArticleGoogle Scholar
- Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, Pawlik M, Peterhoff CM, Yang AJ, Wilson DA, St George-Hyslop P, Westaway D, Mathews PM, Levy E, Cuervo AM, Nixon RA: Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain. 2011, 134: 258-277. 10.1093/brain/awq341.PubMedPubMed CentralView ArticleGoogle Scholar
- Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N: Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006, 441: 885-889. 10.1038/nature04724.PubMedView ArticleGoogle Scholar
- Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006, 441: 880-884. 10.1038/nature04723.PubMedView ArticleGoogle Scholar
- Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura S, Natsume T, Yanagawa T, Uwayama J, Warabi E, Yoshida H, Ishii T, Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E, Tanaka K: Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007, 131: 1149-1163. 10.1016/j.cell.2007.10.035.PubMedView ArticleGoogle Scholar
- Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J, Komatsu M, Abeliovich A: Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegeneration. 2012, 7: 48-View ArticleGoogle Scholar
- Jucker M, Walker LC: Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011, 70: 532-540. 10.1002/ana.22615.PubMedPubMed CentralView ArticleGoogle Scholar
- Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M: Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012, 135: 2169-2177. 10.1093/brain/aws143.PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.